Amarin Corp Plc (AMRN)

[BioChica]

Only if you fall out of the approved indication of Triglycerides greater than 499 and you are a statin user. Some a few insurance companies just do not buy this as a actual problem, so coverage is meek.

The approved FDA label we have is only useful for a small market.

If Vascepa is approved for reduction in CVD for patients of statins with Triglycerides >149. The insurance companies will have greater coverage.

Eventually opening the doors to even more indications will be painfully slow, under the FDA's watchful eye. By then Vascepa will no longer be protected by NCE and patents may be our only protection. I wish they would get approval for Pediatrics to extend NCE. I would rather see children taking EPA rather vs statins.